In conclusion, our study provides a comprehensive molecular sub-characterization of ductal carcinoma in situ (DCIS), revealing a complex landscape of hormone receptor expression, including estrogen receptor (ER), progesterone receptor (PR), as well as human epidermal growth factor receptor (HER2/neu) expression. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.